Martin Rowbottom

Martin Rowbottom is an accomplished professional in the field of medicinal chemistry, currently serving as Executive Director at Genesis Therapeutics since May 2025. Previously, Martin held significant positions including Vice President of Medicinal Chemistry & Structural Biology at Zentalis Pharmaceuticals and Vice President and Head of Chemistry at Gossamer Bio. With experience in various leadership roles, including Senior Director of Medicinal Chemistry at PharmAkea Therapeutics and Associate Director of Medicinal Chemistry at Ambit Biosciences, Martin has demonstrated expertise in innovation and creativity within the pharmaceutical industry. Academic credentials include a PhD in Synthetic Organic Chemistry from the University of Bristol and a BSc in Chemistry from the University of Liverpool.